[Congressional Bills 116th Congress]
[From the U.S. Government Publishing Office]
[H.R. 3772 Introduced in House (IH)]
<DOC>
116th CONGRESS
1st Session
H. R. 3772
To amend title XVIII of the Social Security Act to ensure equitable
payment for, and preserve Medicare beneficiary access to, diagnostic
radiopharmaceuticals under the Medicare hospital outpatient prospective
payment system.
_______________________________________________________________________
IN THE HOUSE OF REPRESENTATIVES
July 16, 2019
Mr. Peters (for himself, Mr. Rush, and Mr. Holding) introduced the
following bill; which was referred to the Committee on Energy and
Commerce, and in addition to the Committee on Ways and Means, for a
period to be subsequently determined by the Speaker, in each case for
consideration of such provisions as fall within the jurisdiction of the
committee concerned
_______________________________________________________________________
A BILL
To amend title XVIII of the Social Security Act to ensure equitable
payment for, and preserve Medicare beneficiary access to, diagnostic
radiopharmaceuticals under the Medicare hospital outpatient prospective
payment system.
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the ``Medicare Diagnostic
Radiopharmaceutical Payment Equity Act of 2019''.
SEC. 2. SEPARATE PAYMENT FOR CERTAIN DIAGNOSTIC RADIOPHARMACEUTICALS.
(a) In General.--Section 1833(t)(16) of the Social Security Act (42
U.S.C. 1395l(t)(16)) is amended by adding at the end the following new
subparagraph:
``(G) Separate payment for certain diagnostic
radiopharmaceuticals.--
``(i) In general.--Notwithstanding any
other provision of this subsection, with
respect to services furnished on or after
January 1, 2020, the Secretary shall not
package, and shall make a separate payment as
specified in clause (ii) for, a diagnostic
radiopharmaceutical defined in clause (v) with
an estimated mean per day product cost equal to
or exceeding the threshold specified in clause
(iii).
``(ii) Separate payment.--For purposes of
clause (i), payment specified in this clause
for a diagnostic radiopharmaceutical described
in clause (i) shall be equal to--
``(I) the average sales price for
the drug established under section
1847A, to the extent the average sales
price is available, as calculated and
adjusted by the Secretary to the extent
such adjustment is adopted for other
specified covered outpatient drugs
under paragraph (14)(A); or
``(II) if the data necessary to
calculate the average sales price for
the drug in the year under the sections
specified in subclause (I) is not
available, the wholesale acquisition
cost as defined in subsection
1847A(c)(6)(B), or, if the wholesale
acquisition cost is not available, the
mean unit cost data derived from
hospital claims data.
``(III) Nothing in this
subparagraph shall be construed as
affecting eligibility of diagnostic
radiopharmaceuticals for pass-through
payments under paragraph (6).
``(iii) Threshold.--For purposes of this
subparagraph, the threshold specified in this
clause--
``(I) for 2020, is $500; and
``(II) for subsequent years, is the
amount specified in this clause for the
preceding year increased by the
percentage of the OPD fee schedule
increase factor under paragraph
(3)(C)(iv) for the applicable year.
``(iv) Budget neutrality.--The Secretary
shall make such adjustments as are necessary
under subparagraph 9(B) to ensure that the
amount of expenditures under this subsection
for such year with application of this
subparagraph is equal to the amount of
expenditures that would be made under this
subsection for such year without application of
this subparagraph.
``(v) Definition.--For purposes of this
subparagraph, a diagnostic radiopharmaceutical
is a drug or biological that is described in
section 315.2(a) of title 21, Code of Federal
Regulations, or any successor regulation, and
is approved by the Food and Drug Administration
on or after January 1, 2008.''.
(b) No Impact on Copayment.--Section 1833(t) of the Social Security
Act (42 U.S.C. 1395l(t)(8)(E)) is amended by--
(1) inserting ``AND SEPARATE PAYMENTS FOR CERTAIN
DIAGNOSTIC RADIOPHARMACEUTICALS'' after ``PASS-THROUGH
ADJUSTMENTS''; and
(2) inserting after ``such adjustments)'' the phrase ``and
subparagraph (16)(G)''.
<all>